Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia

Autor: Raul D. Santos

Publikováno v: Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

OBJECTIVES: Evolocumab, a PCSK9 neutralizing antibody, lowers low-density lipoprotein cholesterol (LDL-C) in Homozygous Familial Hypercholesterolemic (HoFH) patients with reduced LDL receptor (LDLR) function. However, their individual responses are h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd20c4312fa93a552f3f15b4a80c53c8
https://doi.org/10.1161/atvbaha.117.310675

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Autor: Jose C. Nicolau, Jeong-Gun Park, Erin A. Bohula, Jennifer A. White, Robert P. Giugliano, Michael A. Blazing, Eugene Braunwald, Jindřich Špinar, Ramón Corbalán, Christopher P. Cannon

Publikováno v: Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

Background: Ezetimibe, when added to simvastatin, reduces cardiovascular events after acute coronary syndrome. We explored outcomes stratified by diabetes mellitus (DM). Methods: In IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy Interna

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f237cc9c7def27c0a28669931f1f2a32

Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea

Autor: Fernando Ferreira Costa, Fabio T. M. Costa, Camila Bononi De Almeida, Lucas Eduardo Botelho de Souza, Claudio C. Werneck, Dimas Tadeu Covas, Flavia C. Leonardo, Nicola Conran

Publikováno v: Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

Hemolysis and consequent release of cell-free hemoglobin (CFHb) impair vascular nitric oxide (NO) bioavailability and cause oxidative and inflammatory processes. Hydroxyurea (HU), a common therapy for sickle cell disease (SCD), induces fetal Hb produ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fafc5d52fa38e5555b1b2bd5abdbbd57
https://doi.org/10.1182/blood-2014-12-616250

Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases

Autor: Paulo Cesar Cotrim, Gabriel Lima Barros de Araujo, Nadia Araci Bou-Chacra, Raimar Löbenberg, Lis Marie Monteiro

Publikováno v: BioMed Research International
BioMed Research International, Vol 2017 (2017)
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

Buparvaquone (BPQ), a veterinary drug, was formulated as nanostructured lipid carriers (NLC) for leishmaniases treatment. The formulation design addressed poor water solubility of BPQ and lack of human drug delivery system. The DSC/TG and microscopy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a17fa71c628faeb8fa901462b46fc4e

Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the trial to reduce cardiovascular events with aranesp therapy trial

Autor: Patrick S. Parfrey, Andrew S. Levey, Scott D. Solomon, Marc A. Pfeffer, Robert D. Toto, Giuseppe Remuzzi, Finnian R. Mc Causland, Brian Claggett, Kai-Uwe Eckardt, John J.V. McMurray, Ajay K. Singh, Emmanuel A. Burdmann

Publikováno v: Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

Background: The pathogenesis of chronic kidney disease associated anemia is multifactorial and includes decreased production of erythropoietin (EPO), iron deficiency, inflammation, and EPO resistance. To better understand the trajectory of these para

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::538798af62cb6b36c2679e8411b9c50c
https://acuresearchbank.acu.edu.au/item/89yy0/change-in-hemoglobin-trajectory-and-darbepoetin-dose-approaching-end-stage-renal-disease-data-from-the-trial-to-reduce-cardiovascular-events-with-aranesp-therapy-trial